Skip to main content
Fig. 4 | Biomarker Research

Fig. 4

From: A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Fig. 4

High serum IL-1 may predict favorable PFS in HNSCC patients treated with cetuximab-containing therapy. Baseline serum samples from R/M HNSCC patients scheduled for cetuximab-based chemotherapy were collected and serum levels of IL-1α (a) and IL-1β (b) levels were measured by ELISA. Progression free survival was compared for patients with “detectable” versus “undetectable” serum levels of IL-1α (n = 5 vs n = 6 respectively) and IL-1β (n = 4 vs n = 7 respectively)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us